DE69320208D1 - Atovaquon enthaltende arzneizubereitungen - Google Patents

Atovaquon enthaltende arzneizubereitungen

Info

Publication number
DE69320208D1
DE69320208D1 DE69320208T DE69320208T DE69320208D1 DE 69320208 D1 DE69320208 D1 DE 69320208D1 DE 69320208 T DE69320208 T DE 69320208T DE 69320208 T DE69320208 T DE 69320208T DE 69320208 D1 DE69320208 D1 DE 69320208D1
Authority
DE
Germany
Prior art keywords
atovaquon
products containing
medicinal products
medicinal
atovaquone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69320208T
Other languages
English (en)
Other versions
DE69320208T2 (de
Inventor
Alan Roy Dearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of DE69320208D1 publication Critical patent/DE69320208D1/de
Publication of DE69320208T2 publication Critical patent/DE69320208T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fertilizers (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
DE69320208T 1992-12-24 1993-12-23 Atovaquon enthaltende arzneizubereitungen Expired - Lifetime DE69320208T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929226905A GB9226905D0 (en) 1992-12-24 1992-12-24 Pharmaceutical preparation
PCT/GB1993/002646 WO1994014426A1 (en) 1992-12-24 1993-12-23 Atovaquone pharmaceutical compositions

Publications (2)

Publication Number Publication Date
DE69320208D1 true DE69320208D1 (de) 1998-09-10
DE69320208T2 DE69320208T2 (de) 1999-01-21

Family

ID=10727175

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69320208T Expired - Lifetime DE69320208T2 (de) 1992-12-24 1993-12-23 Atovaquon enthaltende arzneizubereitungen

Country Status (36)

Country Link
US (2) US6018080A (de)
EP (1) EP0675711B1 (de)
JP (1) JP3461353B2 (de)
KR (1) KR0175193B1 (de)
CN (1) CN1076194C (de)
AT (1) ATE169215T1 (de)
AU (2) AU675102B2 (de)
BG (1) BG61932B1 (de)
BR (1) BR9307719A (de)
CA (1) CA2152615C (de)
CZ (1) CZ289701B6 (de)
DE (1) DE69320208T2 (de)
DK (1) DK0675711T3 (de)
ES (1) ES2122223T3 (de)
FI (1) FI114007B (de)
GB (1) GB9226905D0 (de)
GE (1) GEP19991515B (de)
HK (1) HK1004086A1 (de)
HR (1) HRP931516B1 (de)
HU (1) HU220215B (de)
IL (1) IL108154A (de)
MY (1) MY109990A (de)
NO (1) NO316745B1 (de)
NZ (1) NZ258995A (de)
PL (1) PL175374B1 (de)
RO (1) RO119686B1 (de)
RU (1) RU2127585C1 (de)
SA (1) SA94140644B1 (de)
SG (1) SG43901A1 (de)
SI (1) SI9300678A (de)
SK (1) SK281924B6 (de)
TW (2) TW514531B (de)
UA (1) UA39879C2 (de)
WO (1) WO1994014426A1 (de)
YU (1) YU48919B (de)
ZA (1) ZA939673B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
WO1996013254A1 (en) * 1994-10-26 1996-05-09 Glaxo Wellcome House Pharmaceutical composition comprising atovaquone
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
EP1056443B1 (de) 1998-02-25 2004-05-06 Abbott Laboratories Butorphanol enthaltende formulierungen mit verzögerter freisetzung
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU2002223500A1 (en) 2000-11-17 2002-05-27 Novo-Nordisk A/S Glucagon antagonists/inverse agonists
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
US7183518B2 (en) * 2004-09-24 2007-02-27 Michael Near System of food storage preparation and delivery in finished cooked state
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
JP5080445B2 (ja) * 2005-04-13 2012-11-21 アボット ゲーエムベーハー ウント コー． カーゲー 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用
US20080241254A1 (en) * 2007-01-02 2008-10-02 Suryakant Navale Pharmaceutical composition comprising atovaquone particles
DE102007001473A1 (de) 2007-01-08 2008-07-10 Andreas Lemke Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
WO2009007991A2 (en) * 2007-04-19 2009-01-15 Ipca Laboratories Limited A new process for preparation of atovaquone and novel intermediates thereof
EP2318350A4 (de) * 2008-07-25 2012-11-28 Alphapharm Pty Ltd ATOVAQUON MIT PARTIKELGRÖSSENDURCHMESSERBEREICH (D90) VON ÜBER 3 muM BIS ZU ETWA 10 muM
US20100099776A1 (en) * 2008-10-20 2010-04-22 Ranbaxy Laboratories Limited Oily suspension of atovaquone
ES2517366T3 (es) 2009-08-20 2014-11-03 Ipca Laboratories Limited Nuevo complejo para el tratamiento y/o profilaxis de infecciones parasitarias
US9023886B2 (en) * 2009-11-10 2015-05-05 Celgene Corporation Nanosuspension of a poorly soluble drug via microfluidization process
WO2011151418A2 (en) 2010-06-02 2011-12-08 Abbott Gmbh & Co. Kg Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase
US10500282B2 (en) 2012-12-19 2019-12-10 Kashiv Biosciences, Llc Supersaturated stabilized nanoparticles for poorly soluble drugs
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3471697A1 (de) * 2016-06-16 2019-04-24 The University of Liverpool Chemische zusammensetzung
US20220265566A1 (en) * 2018-10-18 2022-08-25 Tulex Pharmaceuticals Inc. Atovaquone nanoparticulate compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
NL6411993A (de) * 1963-10-18 1965-04-20
US3347830A (en) * 1964-07-30 1967-10-17 Grace W R & Co Process of polymerizing formaldehyde
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DE2601458A1 (de) * 1975-01-20 1976-07-22 Ciba Geigy Ag Loesliche, von phenylindandiaminen abgeleitete polyamide
EP0002228B1 (de) * 1977-11-22 1984-02-29 The Wellcome Foundation Limited Hydroxynaphtochinonderivate, ihre Präparate zur Behandlung und Verhütung von Theileriose bei Vieh und Schafen; Verfahren zu deren Herstellung; Naphtochinonderivate
US4485117A (en) 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
DE3141691A1 (de) * 1981-10-21 1983-05-19 Hoechst Ag, 6230 Frankfurt Plasmid pac 1, verfahren zu seiner gewinnung und seine verwendung
US5175319A (en) 1983-04-14 1992-12-29 Burroughs Wellcome Co. Naphthoquinone derivatives
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
PL276385A1 (en) * 1987-01-30 1989-07-24 Exxon Chemical Patents Inc Method for polymerization of olefines,diolefins and acetylene unsaturated compounds
IL85097A (en) * 1987-01-30 1992-02-16 Exxon Chemical Patents Inc Catalysts based on derivatives of a bis(cyclopentadienyl)group ivb metal compound,their preparation and their use in polymerization processes
US4783389A (en) * 1987-03-27 1988-11-08 E. I. Du Pont De Nemours And Company Process for preparation of liquid electrostatic developers
US5225500A (en) * 1988-07-15 1993-07-06 Fina Technology, Inc. Process and catalyst for producing syndiotactic polyolefins
US5155080A (en) * 1988-07-15 1992-10-13 Fina Technology, Inc. Process and catalyst for producing syndiotactic polyolefins
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
DE68928964T2 (de) * 1988-08-16 1999-07-29 Wellcome Found Neue Naphthochinone und ihre Anwendung als Arzneimittel
US5225184A (en) * 1988-08-16 1993-07-06 Burroughs Wellcome Co. Medicaments
KR930002411B1 (ko) * 1988-09-14 1993-03-30 미쓰이세끼유 가가꾸고오교오 가부시끼가이샤 벤젠불용성 유기알루미늄 옥시화합물 및 그 제조방법
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
ES2087145T3 (es) * 1989-10-10 1996-07-16 Fina Technology Catalizadores metalocenos con acidos de lewis y alkilo-aluminios.
GB8923254D0 (en) * 1989-10-16 1989-12-06 Wellcome Found Medicaments
US5387568A (en) * 1989-10-30 1995-02-07 Fina Technology, Inc. Preparation of metallocene catalysts for polymerization of olefins
ES2086397T5 (es) * 1989-10-30 2005-07-16 Fina Technology, Inc. Adicion de alkiloaluminio para un catalizador metaloceno mejorado.
DE3942363A1 (de) * 1989-12-21 1991-06-27 Hoechst Ag Verfahren zur herstellung einer polypropylen-formmasse
JP2545006B2 (ja) * 1990-07-03 1996-10-16 ザ ダウ ケミカル カンパニー 付加重合触媒
JP3076619B2 (ja) 1991-05-14 2000-08-14 三井化学株式会社 ブロック共重合体の製造方法
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5766522A (en) * 1996-07-19 1998-06-16 Morton International, Inc. Continuous processing of powder coating compositions
US5976578A (en) * 1996-10-10 1999-11-02 Mcneil-Ppc, Inc. Liquid antacid compositions
US5914135A (en) * 1997-04-16 1999-06-22 Mcneil-Ppc, Inc. Liquid antacid compositions

Also Published As

Publication number Publication date
FI953139A (fi) 1995-06-22
YU80893A (sh) 1997-03-07
FI953139A0 (fi) 1995-06-22
JP3461353B2 (ja) 2003-10-27
BR9307719A (pt) 1999-08-31
HU220215B (hu) 2001-11-28
HK1004086A1 (en) 1998-11-13
ZA939673B (en) 1995-06-23
PL309629A1 (en) 1995-10-30
GEP19991515B (en) 1999-03-05
CN1076194C (zh) 2001-12-19
TW443935B (en) 2001-07-01
HRP931516A2 (en) 1995-10-31
YU48919B (sh) 2002-11-15
CA2152615A1 (en) 1994-07-07
SG43901A1 (en) 1997-11-14
HU9501812D0 (en) 1995-08-28
RU2127585C1 (ru) 1999-03-20
WO1994014426A1 (en) 1994-07-07
AU5710594A (en) 1994-07-19
KR0175193B1 (ko) 1999-02-01
SK82895A3 (en) 1995-11-08
CN1103290A (zh) 1995-06-07
SK281924B6 (sk) 2001-09-11
CZ145195A3 (en) 1995-10-18
AU1627997A (en) 1997-05-22
NO952522L (no) 1995-06-22
TW514531B (en) 2002-12-21
IL108154A (en) 2000-02-17
DE69320208T2 (de) 1999-01-21
AU696662B2 (en) 1998-09-17
ATE169215T1 (de) 1998-08-15
RO119686B1 (ro) 2005-02-28
SI9300678A (en) 1994-09-30
HUT71528A (en) 1995-12-28
EP0675711B1 (de) 1998-08-05
DK0675711T3 (da) 1999-05-03
US6018080A (en) 2000-01-25
CZ289701B6 (cs) 2002-03-13
US6649659B1 (en) 2003-11-18
NZ258995A (en) 1997-01-29
NO952522D0 (no) 1995-06-22
JPH08504805A (ja) 1996-05-28
IL108154A0 (en) 1994-04-12
BG99723A (bg) 1996-01-31
FI114007B (fi) 2004-07-30
PL175374B1 (pl) 1998-12-31
CA2152615C (en) 2001-10-16
EP0675711A1 (de) 1995-10-11
SA94140644B1 (ar) 2005-06-14
KR950703942A (ko) 1995-11-17
AU675102B2 (en) 1997-01-23
BG61932B1 (bg) 1998-10-30
NO316745B1 (no) 2004-04-26
GB9226905D0 (en) 1993-02-17
HRP931516B1 (en) 1999-04-30
ES2122223T3 (es) 1998-12-16
UA39879C2 (uk) 2001-07-16
MY109990A (en) 1997-10-31

Similar Documents

Publication Publication Date Title
DE69320208D1 (de) Atovaquon enthaltende arzneizubereitungen
HUT65278A (en) Process for producing pyrido-, pyrrolo-, thiazino-, oxazino- and pyrazino-benzazepine derivatives and pharmaceutical preparations containing them
HUT65192A (en) Process for producing pyrido-, pyrrolo-, thiazino-, oxazino- and pyrazino benzazepine derivatives and pharmaceutical preparations containing
FI911558A (fi) Menetelmä hapella rikastetun tuotevirran tuottamiseksi
MY113274A (en) Omeprazole magnesium salt form
MA22819A1 (fr) Procede de preparation d'un nouveau produit pharmaceutique.
GR850472B (de)
FI904181A0 (fi) Tislauslaitteisto vetyperoksidin valmistamiseksi
ES2072163T3 (es) Compuestos de inclusion de acido 5,10-metilenotetrahidrofolico y ciclodextrina.
HU9102385D0 (en) Process for the production of medical preparations
FI944507A0 (fi) Menetelmä oksotuotteiden valmistamiseksi
DE59308617D1 (de) 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln
PT87301A (pt) Process for the preparation of 1,3-dioxanes by products and of pharmaceutical compounds containing them
HUT65256A (en) Process for producing 2-mercapto methylene-tetrahydronaphtalene-2-carboxamide derivatives and pharmaceutical preparations containing them
HU890492D0 (en) Process for the production of pharmaceutical preparations for curing dyslipaemia
HUT37430A (en) Process for the production of pteridin-derivatives of pharmaceutical effect
HU9200294D0 (en) Process for the production of medical preparations
EP0498452A3 (en) Process for the production of protease c
HU903473D0 (en) Process for the production of beta-cyclodextrine based inclusion as a medical product
JO1400B1 (en) Method for preparing pharmacy formulations
HU908350D0 (en) Process for the production of medicaments
HU908449D0 (en) Process for the production of medicaments
JO1822B1 (en) A new form of a compound
IT8720906A0 (it) Odorosi, cosmetici e medicamentosi, procedimento e apparecchiatura per e prodotti ottenuti da tale la fabbricazione di unguenti procedimento.
HRP931129A2 (en) Process for the production of protease c

Legal Events

Date Code Title Description
8364 No opposition during term of opposition